O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
View Patent ↗Compositions and formulations comprising insulin or insulin analogs comprising a carboxy terminal portion (CTP) peptide comprising amino acids 112-118 to 145 of the beta subunit of human chorionic gonadotropin (hCGβ) or a partial variant thereof that includes at least one O-glycosylation site of the CTP peptide, wherein the CTP peptide of the CTP peptide-based insulin or insulin analog is O-glycosylated are described. In particular embodiments, the O-glycosylated insulin analogs are produced in vivo and in further embodiments, the O-glycosylated CTP-based insulin analogs comprise predominantly mannotriose and mannotetrose O-glycans or predominantly mannose O-glycans.
1. A composition comprising a conjugate comprising:
An O-glycosylated insulin or insulin analogue having an A-chain peptide comprising the amino acid sequence GIVEQCCTSICSLYQLENYC (SEQ ID NO: 90); a B-chain peptide comprising the amino acid sequence HLCGSHLVEALYLVCGERGFF (SEQ ID NO:3), and a carboxy terminal portion (CTP) peptide comprising amino acids 112-118 to 145 of the beta subunit of human chorionic gonadotropin (hCGβ) that includes at least one O-glycosylation site of the CTP peptide,
wherein at least one amino acid residue of the CTP peptide is covalently linked to an O-glycan wherein the O-glycan in the composition is a mannose, mannobiose, mannotriose, or mannotetrose; and
wherein the insulin or insulin analogue optionally further includes up to 17 amino acid substitutions and the CTP is covalently linked by peptide bond to the N-terminus of the B-chain, the C-terminus of the A-chain, the C-terminus of the B-chain, or the CTP peptide is a connecting peptide that covalently links the B-chain to the A-chain to produce a single-chain insulin or insulin analogue having the structure (B-chain)-(CTP peptide)-(A-chain); and
a pharmaceutically acceptable carrier or salt.
2. The composition of claim 1 , wherein the CTP peptide comprises the amino acid sequence of SEQ ID NO: 1.
3. The composition of claim 1 , wherein the composition comprises the conjugate wherein greater than 50 mole % of the O-glycans are mannotriose and mannotetrose.
4. The composition of claim 1 , wherein the composition comprises the conjugate wherein greater than 80 mole % of the O-glycans are mannotriose and mannotetrose.
5. The composition of claim 1 , wherein the mannose residues are covalently linked to an adjacent mannose residue by α1,2-linkage.
6. The composition of claim 1 , wherein the composition comprises the conjugate wherein greater than 95 mole % of the O-glycans are mannose.
7. The composition of claim 1 , wherein the composition lacks detectable β-linked mannose, phosphomannose, or β-linked mannose and phosphomannose.
8. The composition of claim 1 , wherein the insulin or insulin analogue is a heterodimer or a single-chain.
9. A pharmaceutical formulation comprising:
(a) a multiplicity of conjugates comprising O-glycosylated insulin or insulin analogues, each O-glycosylated insulin or insulin analogue having a carboxy terminal portion (CTP) peptide comprising amino acids 112-118 to 145 of the beta subunit of human chorionic gonadotropin (hCGβ) that includes at least one O-glycosylation site of the CTP peptide, wherein at least one amino acid residue of the CTP peptide is covalently linked to an O-glycan wherein the O-glycan in the composition is a mannose, mannobiose, mannotriose, or mannotetrose, and
(b) a pharmaceutically acceptable carrier or salt.
10. The composition of claim 9 , wherein the CTP peptide comprises the amino acid sequence of SEQ ID NO: 1.
11. The composition of claim 9 , wherein the composition comprises the conjugate wherein greater than 50 mole % of the O-glycans are mannotriose and mannotetrose.
12. The composition of claim 9 , wherein the composition comprises the conjugate wherein greater than 80 mole % of the O-glycans are mannotriose and mannotetrose.
13. The composition of claim 9 , wherein the mannose residues are covalently linked to an adjacent mannose residue by α1,2-linkage.
14. The composition of claim 9 , wherein the composition comprises the conjugate wherein greater than 95 mole % of the O-glycans are mannose.
15. The composition of claim 9 , wherein the composition lacks detectable β-linked mannose, phosphomannose, or β-linked mannose and phosphomannose.
16. The composition of claim 9 , wherein the insulin or insulin analogue is a heterodimer or a single-chain.